Core Viewpoint - The article discusses the impact of President Trump's warning to pregnant women about the use of Tylenol (acetaminophen), linking it to autism, which led to a significant drop in Kenvue's stock price. However, medical professionals and Kenvue refute this claim, stating there is no scientific evidence supporting such a connection [2][3][7]. Group 1: Stock Market Reaction - Kenvue's stock price fell over 7% to a historical low of $32.57, resulting in a market capitalization of $32.567 billion (approximately 231.6 billion RMB) following Trump's warning [3]. - Following the backlash and lack of scientific support for Trump's claims, Kenvue's stock rebounded by over 5% in pre-market trading [2][3]. Group 2: Medical Community Response - Numerous doctors and Kenvue have stated that there is no scientific evidence linking acetaminophen to autism, emphasizing that such claims could endanger the health of pregnant women [2][7]. - The FDA has indicated that there is no clear evidence that appropriate use of acetaminophen during pregnancy leads to adverse outcomes [5]. Group 3: Research and Studies - A large-scale study published in 2024 analyzing data from nearly 2.5 million siblings in Sweden found no increased risk of autism in children whose mothers used acetaminophen during pregnancy [4]. - The article notes that the diagnosis rate of autism has significantly increased in the U.S., with 1 in 31 children diagnosed, compared to 1 in 150 in 2000, although the reasons for this rise remain unclear [6]. Group 4: Government and Pharmaceutical Company Actions - U.S. health officials are expected to issue warnings against the use of Tylenol during early pregnancy unless necessary, while also promoting a drug called Leucovorin as a potential treatment for autism [8]. - Kenvue has added a section on its website to address media reports, reiterating that there is no evidence linking acetaminophen to autism [7].